Shineco, Inc. (SISI)
USD 2.12
(-4.07%)
USD 2.12
(-4.07%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 882.16 Thousand USD | 599.11% |
| 2023 | 126.18 Thousand USD | 107.83% |
| 2022 | -1.61 Million USD | 61.98% |
| 2021 | -4.23 Million USD | -169.22% |
| 2020 | 6.11 Million USD | -31.79% |
| 2019 | 8.97 Million USD | -39.33% |
| 2018 | 14.78 Million USD | 37.68% |
| 2017 | 10.74 Million USD | -3.11% |
| 2016 | 11.08 Million USD | 7.12% |
| 2015 | 10.34 Million USD | 7.87% |
| 2014 | 9.59 Million USD | 1.91% |
| 2013 | 9.41 Million USD | 0.0% |
| 2006 | 1.27 Million USD | -31.73% |
| 2005 | 1.86 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | -1.15 Million USD | -469.26% |
| 2024 Q1 | 98.95 Thousand USD | 104.51% |
| 2024 Q2 | 312.31 Thousand USD | 215.62% |
| 2024 Q4 | 279.22 Thousand USD | 124.21% |
| 2023 Q1 | -90.87 Thousand USD | -152.43% |
| 2023 Q2 | -119.86 Thousand USD | -31.9% |
| 2023 Q4 | -2.19 Million USD | -2342.84% |
| 2023 Q3 | -89.86 Thousand USD | 25.03% |
| 2023 FY | 126.18 Thousand USD | 107.83% |
| 2022 Q2 | -561.69 Thousand USD | 23.01% |
| 2022 FY | -1.61 Million USD | 61.98% |
| 2022 Q1 | -729.54 Thousand USD | 89.09% |
| 2022 Q4 | 173.31 Thousand USD | 135.17% |
| 2022 Q3 | -492.74 Thousand USD | 12.28% |
| 2021 Q2 | -2.65 Million USD | -392.22% |
| 2021 Q1 | 908.58 Thousand USD | -46.7% |
| 2021 Q3 | -1 Million USD | 62.06% |
| 2021 Q4 | -6.68 Million USD | -564.1% |
| 2021 FY | -4.23 Million USD | -169.22% |
| 2020 Q1 | 1.63 Million USD | -22.05% |
| 2020 Q2 | 2.36 Million USD | 44.22% |
| 2020 Q3 | 410.12 Thousand USD | -82.66% |
| 2020 Q4 | 1.7 Million USD | 315.68% |
| 2020 FY | 6.11 Million USD | -31.79% |
| 2019 Q4 | 2.1 Million USD | -10.74% |
| 2019 Q3 | 2.35 Million USD | -1.8% |
| 2019 FY | 8.97 Million USD | -39.33% |
| 2019 Q1 | 2.11 Million USD | -19.41% |
| 2019 Q2 | 2.4 Million USD | 13.7% |
| 2018 Q4 | 2.61 Million USD | -50.22% |
| 2018 FY | 14.78 Million USD | 37.68% |
| 2018 Q3 | 5.26 Million USD | 9.22% |
| 2018 Q2 | 4.81 Million USD | 130.7% |
| 2018 Q1 | 2.08 Million USD | -7.97% |
| 2017 Q4 | 2.26 Million USD | -12.81% |
| 2017 Q1 | 1.91 Million USD | -12.21% |
| 2017 Q2 | 3.95 Million USD | 106.46% |
| 2017 Q3 | 2.6 Million USD | -34.17% |
| 2017 FY | 10.74 Million USD | -3.11% |
| 2016 Q3 | 2.17 Million USD | -49.74% |
| 2016 Q1 | 2.41 Million USD | 20.0% |
| 2016 Q4 | 2.18 Million USD | 0.47% |
| 2016 FY | 11.08 Million USD | 7.12% |
| 2016 Q2 | 4.31 Million USD | 79.06% |
| 2015 FY | 10.34 Million USD | 7.87% |
| 2015 Q4 | 2.01 Million USD | -15.48% |
| 2015 Q3 | 2.37 Million USD | -33.31% |
| 2015 Q2 | 3.56 Million USD | 49.11% |
| 2015 Q1 | 2.39 Million USD | 8.76% |
| 2014 Q4 | 2.19 Million USD | 2.95% |
| 2014 Q2 | 2.64 Million USD | 0.0% |
| 2014 Q3 | 2.13 Million USD | -19.24% |
| 2014 Q1 | 2.64 Million USD | -16.65% |
| 2014 FY | 9.59 Million USD | 1.91% |
| 2013 Q4 | 3.17 Million USD | 35.43% |
| 2013 FY | 9.41 Million USD | 0.0% |
| 2013 Q3 | 2.34 Million USD | 0.0% |
| 2007 Q3 | 325.29 Thousand USD | 0.0% |
| 2007 Q1 | 275.25 Thousand USD | 0.0% |
| 2006 Q3 | 271.48 Thousand USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | 1.27 Million USD | -31.73% |
| 2005 FY | 1.86 Million USD | 0.0% |
| 2005 Q3 | 456.75 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Theratechnologies Inc. | 62.12 Million USD | 98.58% |
| Harrow Health, Inc. | 90.55 Million USD | 99.026% |
| Dynavax Technologies Corporation | 182.11 Million USD | 99.516% |
| Biofrontera Inc. | 16.62 Million USD | 94.694% |
| Cronos Group Inc. | 6.99 Million USD | 87.381% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | 81.408% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 99.8% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 391.145% |
| RedHill Biopharma Ltd. | 3.05 Million USD | 71.116% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 97.366% |
| Radius Health, Inc. | 307.71 Million USD | 99.713% |
| Universe Pharmaceuticals INC | 10.07 Million USD | 91.246% |
| DURECT Corporation | 6.83 Million USD | 87.086% |
| ProPhase Labs, Inc. | 16.23 Million USD | 94.568% |
| Safety Shot Inc | -74.45 Thousand USD | 1284.802% |
| Phibro Animal Health Corporation | 312.48 Million USD | 99.718% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -59.244% |
| Alvotech | -69.42 Million USD | 101.271% |
| Assertio Holdings, Inc. | 125.04 Million USD | 99.295% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 99.832% |
| Rockwell Medical, Inc. | 8.7 Million USD | 89.865% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | 89.421% |
| Procaps Group S.A. | 239.56 Million USD | 99.632% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 99.795% |
| SCYNEXIS, Inc. | 124.51 Million USD | 99.292% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 98.384% |
| Viatris Inc. | 6.43 Billion USD | 99.986% |
| OptiNose, Inc. | 62.35 Million USD | 98.585% |
| SIGA Technologies, Inc. | 122.09 Million USD | 99.277% |
| Tilray Brands, Inc. | 223.35 Million USD | 99.605% |
| PetIQ, Inc. | 252.74 Million USD | 99.651% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | 89.421% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.952% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | 83.647% |
| Alimera Sciences, Inc. | 61.17 Million USD | 98.558% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 99.73% |
| Silver Spike Investment Corp. | 8.1 Million USD | 89.113% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 13052.107% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 99.715% |
| Journey Medical Corporation | 52.52 Million USD | 98.32% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | 78.952% |
| Alpha Teknova, Inc. | 10.29 Million USD | 91.432% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | 86.544% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | 97.892% |
| PainReform Ltd. | -15 Thousand USD | 5981.12% |
| Cosmos Health Inc. | 4.34 Million USD | 79.718% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | 96.747% |
| TherapeuticsMD, Inc. | 1.3 Million USD | 32.245% |
| Embecta Corp. | 749.9 Million USD | 99.882% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 218.318% |
| Talphera, Inc. | -4.89 Million USD | 118.022% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 99.82% |
| Incannex Healthcare Limited | 12 Thousand USD | -7251.4% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 136.602% |
| Procaps Group, S.A. | 239.56 Million USD | 99.632% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 99.711% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | 97.035% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 99.876% |
| Alvotech | -69.42 Million USD | 101.271% |
| Hempacco Co., Inc. | -1.21 Million USD | 172.557% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 99.602% |
| Bright Green Corporation | -237.01 Thousand USD | 472.198% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 98.793% |
| Kamada Ltd. | 52.59 Million USD | 98.323% |
| Indivior PLC | 907 Million USD | 99.903% |
| Evoke Pharma, Inc. | 4.97 Million USD | 82.281% |
| Flora Growth Corp. | 17.73 Million USD | 95.027% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 136.602% |
| Evolus, Inc. | 140.52 Million USD | 99.372% |
| HUTCHMED (China) Limited | 453.55 Million USD | 99.805% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 99.744% |
| Akanda Corp. | 111.44 Thousand USD | -691.544% |